Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …

One of the major breakthroughs to combat the current Coronavirus Disease 2019 (COVID-
19) pandemic has been the development of highly effective vaccines against the Severe …

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), has developed into a global pandemic since its first outbreak …

Rapidly emerging SARS-CoV-2 variants jeopardize antibody-based countermeasures.
Although cell culture experiments have demonstrated a loss of potency of several anti-spike …

Omicron and its subvariants have rendered most authorized monoclonal antibody-based
treatments for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ineffective …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal
antibodies (mAbs) can reduce the risk of hospitalization from coronavirus disease 2019 …

Due to the continuous evolution of SARS-CoV-2, the Omicron variant has emerged and
exhibits severe immune evasion. The high number of mutations at key antigenic sites on the …

Development of effective therapeutics for mitigating the COVID-19 pandemic is a pressing
global need. Neutralizing antibodies are known to be effective antivirals, as they can be …

Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for
therapies. However, the effectiveness of many antibodies has been reduced against recently …

The emergence of highly transmissible SARS-CoV-2 variants of concern (VOC) that are
resistant to therapeutic antibodies highlights the need for continuing discovery of broadly …